Details

Autor(en) / Beteiligte

• Poole, Jeanne E
• Johnson, George W
• Hellkamp, Anne S
• Anderson, Jill
• Callans, David J
• Raitt, Merritt H
• Reddy, Ramakota K
• Marchlinski, Francis E
• Yee, Raymond
• Guarnieri, Thomas
• Talajic, Mario
• Wilber, David J
• Fishbein, Daniel P
• Packer, Douglas L
• Mark, Daniel B
• Lee, Kerry L
• Bardy, Gust H

Titel

Prognostic Importance of Defibrillator Shocks in Patients with Heart Failure

Ist Teil von

• The New England journal of medicine, 2008-09, Vol.359 (10), p.1009-1017

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2008

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• In the Sudden Cardiac Death in Heart Failure Trial, 811 patients were randomly assigned to receive implantable cardioverter–defibrillators (ICDs). Of these patients, 269 (33.2%) received at least one ICD shock over a median follow-up period of 45.5 months. The occurrence of ICD shocks, whether appropriate or inappropriate, was associated with a significant increase in the subsequent risk of death from all causes. The occurrence of ICD shocks, whether appropriate or inappropriate, was associated with a significant increase in the subsequent risk of death from all causes. The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) (ClinicalTrials.gov number, NCT00000609) and the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) both showed that therapy with implantable cardioverter–defibrillators (ICDs) improves survival among patients who are at risk for sudden cardiac death but who have not previously had a sustained ventricular arrhythmia. 1 – 3 On the basis of these data, recent clinical guidelines consider the implantation of an ICD for “primary prevention” (i.e., prevention of a first life-threatening arrhythmic event) to be standard high-quality care for patients who meet the entry criteria for these trials. 4 One result of this broader use . . .